PITCH DECK PRESENTATION

ON

A NOVEL RECOMBINANT TICK VACCINE (JUTVAC-NG) FOR AN INTERGRATED CONTROL OF TICKS IN WEST AFRICA

PROFESSOR GONI ABRAHAM DOGO

(Inventor)





BRIEF



One of the major stumbling blocks in the development of anti-tick vaccines, as with other anti-parasite vaccines, is the identification of effective antigens (Willadsen 2008).



In this project, a systematic and pragmatic approach to express the BM86 protein for the development of a novel recombinant tick vaccine for an integrated control of ticks and infectious pathogens they transmit from livestock to humans in Nigeria is being proposed.



This was inspired when, cattle vaccinated with crude extracts of the infesting ticks resulted in a reduction in the tick burden.



In addition, the team has modelled the efficacy of the TICKGARD VACCINE in the Nigerian ticks and have gone further to practically characterized the BM86 genes in Nigeria (Dogo et al., 2010).

BRIEF PROJECT BACKGROUND CONTD.

- ► Efforts in tick vaccine research and development have been made in the western world, but complimentary efforts have been lacking in Africa.
 - ❖ Dispite its high relevance to the livestock industry until recently, significant immunogenic BM86 gene were isolated, sequenced and characterized from Nigerian pathogenic ticks.
 - * Boophilus annulatus, Boophilus decoloratus and Hyalomma truncatum in central part of Nigeria, Dogo et al, 2015.
 - ❖The BM86 gene sequences have been allotted accession numbers as KF670599, KF670600 and KF670601 respectively and deposited in the GenBank of national centre for biotechnology information (NCBI) which will be retrieved and used as the starting material for this project.

PROJECT OBJECTIVES

- General objectives:
 - 1. Improve animal health.
 - 2. Increase livestock production thereby ensuring food security.
 - 3. Promote innovative technologies in vaccine development.
 - 4. Advance collaboration in research and development.
 - 5. Boost economic prosperity of the nation


• Protein Sequence

PROTEIN LENGTH = 654

MW = 72990.5 PREDICTED PI = 6.82

MLLVNQSHQGFNKEHTSKMVSAIVLYVLLAAAAHSAFAESSICSDFGNEFCRNAECEVVPGAEDDFVCKCPRDNMYFNAAEKQCEYKDTCKTRECSYGRCVESNPSKGSCVCEASDDLTLQCKIKKDFATDCRNRGTAKLRTDGFIGATCDCGEWGAMNKTTRNCVPTTCLRPDLTCKDLCEKNLLQRDSRCCQGWNTANCSAAPPADSYCSPGSPKGPDGQCKNACRTKEAGFVCKHGCRSTDKAYECTCPSGFTVAEDGITCKSISYTVSCTVEQKQTCRPTEDCRVQKGTVLCECPWNQHLVGDTCISDCVDKKCHEEFMDCGVYMNRQSCYCPWKSRKPGPNVNINECLLNEYYYTVSFTPNISFDSDHCKRYEDRVLEAIRTSIGKEVFKVEILNCTQDIKARLIAEKPLSKYVLRKLQACEHPIGEWCMMYPKLLIKKNSATEIEEENLCDSLLKNQEAAYKGQNKCVKVDNLFWFQCADGYTTTYEMTRGRLRRSVCKAGVSCNENEQLECANKGQICVYENGKANCQCPPDTKPGEIGCIERTTCNPKEIQECQDKKLECVYKNHKAECKCPDDHECSRQPAKDSCSEEDNGKCQSSGQRCVMENGKAVCKEKSEATTAATTTTKAKDKDPDPGKSSLEHHHHHHH***

SDS-PAGE & western blot analysis:



- •Lane M1: protein marker, Bio-rad, Cat. No. 1610374S, refer to annotated key on the left for size
- •Lane M2: protein marker, GenScript, Cat. No. M00673, refer to annotated key on the left for size
- •BSA: 2.00 μg
- •R: reducing condition
- •Primary antibody: mouse-anti-his mab (GenScript, cat. No. A00186)

VACCINE FORMULATION AT NVRI-VOM.


- Procurement, assembling of materials and development of SOP Cont'd.
 - ✓ Material for vaccine formulation at NVRI-Vom (objective 5) has been fully paid for, supplied and sop fully developed
 - ✓ Material for vaccine quality control and quality assurance (objective 6) has been fully paid for, supplied and SOP fully developed
 - ✓ Material to conduct in-vitro assessment of the novel vaccine in mice (objective 7) has been fully paid for, 80% supplied and SOP fully developed.
- Ticks' collection and rearing
 - ✓ Ticks' collection and rearing has been fully completed.




• THE ANTI-TICK VACCINES



PATENT REGISTRATION CERTIFICATE





STI-AWARD 2024



The project got the 1st position science and innovation Award (Tertiary Category) 2024, accompanied with One Million Naira cash award.







MOLECULAR BIOLOGY AND PROTEOMICS TRAINING WORKSHOP FOR POSTGRADUATE STUDENTS AND STAFF AT UNIJOS



A NOVEL DNA POLYVALENT ANTI-TICK VACCINE

(JUTVAC-NG®) / (DOGVAC-N®)

This invention discloses two novel DNA anti-tick vaccines, JUTVAC-NG™ for Cattle, Sheep and Goats and DOGVAC-N™ for Dogs. These vaccines are formulated using a proprietary blend of antigens (BM86 orthologs) derived from three pathogenic tick gut proteins in Nigeria, ensuring a targeted and robust immune response in the respective animal hosts in Africa.



P.M.B 2084, Jos 93001, Nigeria

website: www.unijos.edu.ng

email: dogoa@unijos.edu.ng, gonidogo@gmail.com


Contact: +234 8034 501 914



A NOVEL DNA POLYVALENT ANTI-TICK VACCINE

(JUTVAC-NG®) / (DOGVAC-N®)

This invention discloses two novel DNA anti-tick vaccines, JUTVAC-NG™ for Cattle, Sheep and Goats and DOGVAC-N™ for Dogs. These vaccines are formulated using a proprietary blend of antigens (BM86 orthologs) derived from three pathogenic tick gut proteins in Nigeria, ensuring a targeted and robust immune response in the respective animal hosts in Africa.



P.M.B 2084, Jos 93001, Nigeria

website: www.unijos.edu.ng

email: dogoa@unijos.edu.ng, gonidogo@gmail.com Contact: +234 8034 501 914



A NOVEL DNA POLYVALENT ANTI-TICK VACCINE

(JUTVAC-NG®) / (DOGVAC-N®)

This invention discloses two novel DNA anti-tick vaccines, JUTVAC-NG™ for Cattle, Sheep and Goats and DOGVAC-N™ for Dogs. These vaccines are formulated using a proprietary blend of antigens (BM86 orthologs) derived from three pathogenic tick gut proteins in Nigeria, ensuring a targeted and robust immune response in the respective animal hosts in Africa.



P.M.B 2084, Jos 93001, Nigeria

website: www.unijos.edu.ng email: dogoa@unijos.edu.ng, gonidogo@gmail.com

Contact: +234 8034 501 914

